Merck’s Oncology Engine Is Still Accelerating (NYSE:MRK)
· seekingalpha.com
Merck & Co., Inc. stock outlook: FDA approves Keytruda combo for kidney cancer as sales rise. Click here for this MRK update.
At the end of April, I published an article , "Merck: Bullish Setup Into Q1 Earnings," in which I initially aimed to present the factors that would lead Merck &...